Groundbreaking research presented at ASCO with Dr. Elinor Barsh, MD, and Dr. Jacob Keeling, MD, focuses on advances in immunotherapy for CTLA-4 resistant melanoma. This episode highlights the importance of recent progress, including the Phase I study of the antibody–drug conjugate ozuriftamab vedotin. Dr. Barsh and Dr. Keeling discuss new clinical trial data, evolving treatment pathways, and the significant reduction in mortality rates achieved with novel therapies. Their collaboration with the Sarah Cannon Research Institute underscores how innovative research can transform patient outcomes making melanoma more manageable despite its aggressive nature.